ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 602

Repeat Biopsy In Lupus Nephritis: A Single-Center Experience

Josefina Marin1, Marina Scolnik2, Eliana Lancioni3, Gustavo Greloni4, Cristian Quiroz5, Johana Zacariaz3, Carla Saucedo6, Luis J. Catoggio2 and Enrique R. Soriano2, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 3Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: biopsies, Nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Renal involvement in systemic lupus erythematosus (SLE) is an important cause of morbidity and even mortality. Lupus nephritis has diverse morphologic manifestations with varying clinical presentations and consequences.Treatment and prognosis accordingly range from excellent even with only observation with minimal mesangial deposits, to kidney failure despite aggressive immunosuppression in patients with severe proliferative disease. Renal biopsy plays a crucial role in the diagnosis of the specific form of lupus nephritis, and rebiopsy is often necessary during follow up in order to assess renal activity and guide treatment.  The objective of our study was to describe characteristics of second biopsies in SLE patients and try to identify variables useful for prediction of histological form of lupus nephritis in second biopsies.

Methods: SLE patients (ACR criteria) who had a diagnosis of lupus nephritis and two or more renal biopsies after year 2001 were included. Electronic medical records were reviewed and clinical, laboratory and treatment data were obtained from each patient. Renal biopsy was classified according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of lupus nephritis. 

Results: we identified 45 lupus patients (40 females) with at least two renal biopsies. These patients had a total of 116 biopsies. Class IV (51,8%) and V (17,2%) were the most frequent findings. Treatments received are shown in table 1. Laboratory findings at the moment of biopsy are shown in table 2 and showed no significant differences between different histology patterns. In multivariable analysis no variable was significantly associated with any histology class at time of the second biopsy. 27 patients (64%) changed histology class between successive biopsies. Those who did not change were mostly class IV (68.8%). 55 rebiopsies (82%) generated a treatment modification and 12 (18%) did not (insufficient data from 6). 

Table 1. Treatment received after renal biopsies.

Induction treatment

Maintenance treatment

IV Cyclophosphamide >= 6  pulses (33%)

Mycophenolate (45,7%)

Mycophenolate (22,4%)

Azathioprine (17%)

IV cyclophosphamide < 6 pulses (13%)

Cyclophosphamide

(9.5%)

Rituximab (8%)

Others (8,6%)

Others (21%)

 

Table 2. Laboratory features at time of second biopsy.

 

Class II

 

Class III

 

Class IV

Class V

 

Combination b/ III or IV + V

Mean proteinuria (g/24 hs)

0.92

1.24

2.29

3.57

5.92

Mean creatinine (mg/dl)

0.98

1.14

1.27

1.16

1

Patients with hematuria, (>4 RBC), %

88.9%

60%

69%

50%

50%

Mean Albumin (g/dl)

3.05

3.39

2.8

2.93

2.4

 Low C3, %

57.1 %

33%

76.7 %

50 %

67%

DNA +, %

66.7%

44.5%

81.8%

26.7%

50%

Conclusion: In this lupus nephritis cohort, 64 % of patients with a repeated biopsy showed change in the histological class. We were unable to identify variables capable of predicting histological class in second biopsies. In 82% of patients second biopsy was associated with treatment change.


Disclosure:

J. Marin,
None;

M. Scolnik,
None;

E. Lancioni,
None;

G. Greloni,
None;

C. Quiroz,
None;

J. Zacariaz,
None;

C. Saucedo,
None;

L. J. Catoggio,
None;

E. R. Soriano,

Abbott Immunology Pharmaceuticals,

2,

Bristol-Myers Squibb,

2,

Genzyme Corporation,

2,

Pfizer Inc,

8,

Abbott Immunology Pharmaceuticals,

8,

Janssen Pharmaceutica Product, L.P.,

8,

UCB,

8,

Bristol-Myers Squibb,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/repeat-biopsy-in-lupus-nephritis-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology